FEB 24 2022 Webinar: Real World Data
New Frontiers in the RWD and Current Use-Cases for RWD Collection
Powered by AMS and Glatt Pharmaceutical Services
Fewer than half of new drugs have data on their comparative benefits and harms against existing treatment options at the time of regulatory approval in Europe and the USA. Comparative evidence generation is even sparser for medical devices. Use of non-randomised studies for the evaluation of clinical benefit in the post-marketing period should be limited to instances when the magnitude of effect is deemed to be large or when it is possible to reasonably infer the comparative benefits or risks in settings, in which doing a randomised trial is not feasible.
Speakers are Harald Wagner (Director Clinical Operations) and Kirsten Dahm (Medical Writer and Digital Health Application Expert), both AMS.
Feb 24, 2022 03:00 PM in Amsterdam, Berlin, Rome, Stockholm, Vienna
Please, find the registration link here.
Get in touch with us at: Research@ams-europe.com